Published Date: 02 Mar 2023
Researchers from the University of Queensland have confirmed that genes associated with the risk of Parkinson's disease also contribute to the production of cellular debris in the brain.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
Best foot forward—chemo care should include podiatry, say researchers
2.
World's premier cancer institute faces crippling cuts and chaos
3.
On all CAR-T products, the FDA is calling for a new boxed warning.
4.
Treating advanced prostate cancer
5.
Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
1.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
2.
Citizen-Centered Digital Health Navigation Systems: Advancing Patient Engagement and Optimizing Healthcare Delivery
3.
Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers
4.
What You Need to Know About Correcting Calcium Levels in Patients with Low Albumin
5.
A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
2.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation